WEBULL
News
CING
3.990
+1.27%
0.050
Weekly Report: what happened at CING last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at CING last week (1117-1121)?
Weekly Report · 11/24 10:34
Cingulate Price Target Cut to $16.00/Share From $17.00 by Roth Capital
Dow Jones · 11/19 18:10
Cingulate Is Maintained at Buy by Roth Capital
Dow Jones · 11/19 18:10
Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $16
Benzinga · 11/19 18:00
Cingulate price target lowered to $16 from $17 at Roth Capital
TipRanks · 11/19 00:55
Cingulate Inc. Signs Exclusive Commercial Supply Agreement with Bend Bio Sciences
Reuters · 11/18 21:28
Weekly Report: what happened at CING last week (1110-1114)?
Weekly Report · 11/17 10:35
Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment
TipRanks · 11/15 16:25
Cingulate reports Q3 results
Seeking Alpha · 11/13 18:04
Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year
TipRanks · 11/13 13:16
Biopharma firm Cingulate's Q3 net loss widens, misses analyst expectations
Reuters · 11/13 13:09
Cingulate Inc. posts third quarter loss of $6.0 million
Reuters · 11/13 13:00
CINGULATE Q3 NET INCOME USD -7.3 MILLION VS. IBES ESTIMATE USD -3.82 MILLION
Reuters · 11/13 13:00
Cingulate Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Bryan Wade Downey
Reuters · 11/10 23:00
Cingulate Inc Signs Note Purchase Agreement with Avondale
TipRanks · 11/10 13:50
Cingulate names Downey as CCO to lead launch prep for CTx-1301
TipRanks · 11/10 13:25
Cingulate Inc. Appoints Bryan Downey as Chief Commercial Officer
Reuters · 11/10 13:03
Press Release: Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Dow Jones · 11/10 13:00
Weekly Report: what happened at CING last week (1103-1107)?
Weekly Report · 11/10 10:31
More
Webull provides a variety of real-time CING stock news. You can receive the latest news about Cingulate Inc through multiple platforms. This information may help you make smarter investment decisions.
About CING
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.